Laura Asensio Jurado
Barcelona, Spain
NCT Number: NCT04313257
This study evaluates the effectiveness of the monocular treatment with action video-games in comparison with the occlusion therapy alone in amblyopic patients, and the satisfaction with the different evaluated treatments.
Looking for future studies?
Notify Me4 year–10 year
All sexes
Interventional
Not applicable
Barcelona, Spain
Amblyopia is the condition in which there is a decrease in monocular visual acuity or, less frequently, binocular, in absence of structural anomalies or ocular pathology. It is a reversible condition that affects up to 5% of the population, and that is the result of an abnormal visual experience during the most sensitive period of visual development.
The aim of this study is reviewing, analyzing and, if applicable, updating the current treatment model for amblyopia.
A randomized clinical trial will be performed to evaluate the effectiveness of the monocular treatment with action video-games in comparison with the occlusion therapy alone in amblyopic patients, and the satisfaction with the different evaluated treatments. The participants will be distributed in two groups. The first group will include those participants who will follow a daily occlusive treatment and the second group will include patients who will be treated with monocular therapy with video-games.The sample will include subjects between 4 to 10 years old with a diagnosis of refractive and / or strabismic amblyopia.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Occlusion treatment of one hour daily with action video game.
Occlusion treatment of two hour daily.
Time frame: Baseline and 14, 28 and 42 hours post treatment.
Visual Acuity (VA in logMAR) will be evaluated by E Snellen Test through an Ipad and the app AmblyopiaVA. The AmblyopiaVA test is designed based on the standard protocol for measuring Visual Acuity in children with Amblyopia.The measure will be performed at 2 m.
Time frame: Baseline and 14, 28 and 42 hours post treatment.
Stereopsis (ST in logMAR) will be evaluated by a Multiple Random Points test through an Ipad, the app StereoTAB and anaglyphic glasses. The measures will be performed at 50 cm.
Time frame: Baseline and 14, 28 and 42 hours post treatment.
The effect of treatment on Contrast Sensitivity Function (CSF in logMAR) will be evaluated by ClinicCFS test using sine grids of four different spatial frequencies: 3, 6, 12 and 18 cpd.
Time frame: 42 hours
Satisfaction assessed by an ordinal questionnaire (1 to 5, as 1 the lowest satisfaction and 5 the highest satisfaction),based on the TSQM (Treatment Satisfaction Questionnaire for Medication) version 1.4 to provide data regarding the degree of satisfaction and sensation of parents and children in relation to treatment.
Time frame: Baseline and 14h, 28h and 42 hours.
Rate of Compliance assessed through the registration of parent-reported adherence and log file data in Google Analytics (descriptive scale of time in hours/day) for active group and parent's questionnaire for passive group (subjective scale in hours/day)
Universitat Politècnica de Catalunya
Other
Monocular Action Video Game Versus Passive Occlusion In The Treatment Of Amblyopia: A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04315649
Amblyopia, Anisometropic Amblyopia
Barcelona, Spain
View Trial DetailsNCT06372548
Adherence, Treatment, Amblyopia
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT02983552
Amblyopia, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05732467
Amblyopia, Brain Diseases
Hangzhou, Zhejiang, China
View Trial Details